A vaccine is a suspension of weakened, killed, or fragmented microorganisms or toxins or of antibodies or lymphocytes that is administered to stimulate the body's immune response against the specific infectious agent or disease. Intramuscular is the most common mode of administration for vaccines. Majorly vaccines can be categorized into the following types based on their characteristics:
- Live-attenuated vaccines
- Inactivated vaccines
- Subunit, recombinant, conjugate, and polysaccharide vaccines
- Toxoid vaccines
- mRNA vaccines
- Viral vector vaccines
Read report summary or request a free sample copy of the report “Vaccine Industry Procurement Intelligence, Supplier Intelligence, Supplier Ranking, Pricing & Cost Structure Intelligence, Best Practices, Engagement Model, Low & Best Cost Country, Day One Analysis Report, 2020 – 2027”
Demand Outlook
The global vaccine market was valued at USD 42 billion in 2020 and it is expected to grow at a CAGR of 7-8% from 2020 to 2027 due to the high prevalence of infectious diseases, increasing company initiatives to enhance vaccine R&D, growing government investments for vaccine development, and the rising focus on immunization. According to WHO immunization awareness and government initiatives have helped prevent 2-3 million deaths annually before Covid-19. The recombinant/conjugate vaccine segment is the largest market share of ~55% followed by inactivated and live attenuated vaccines. North America generated more than 35% of revenue of the global vaccine market owing to strong awareness, secure government policies regarding health welfare.
Cost Drivers
Vaccine manufacturing costs can be divided into two segments. Fixed costs and variable costs. Fixed costs include product development, facilities, and equipment costs. Variable costs include consumables, direct labor, licensing/regularization, commercialization, and overhead costs. Vaccine production costs have a significant fixed cost component, reaching up to 90% of total costs. Production costs per unit can be reduced significantly through gains in productivity and economies of scale. Because of the high fixed cost element, the cost of production per dose decreases with increasing batch size. For bulk production, equipment cost is the major cost component with more than 40% share in the overall cost of production. Whereas for lab-scale production the product development and raw material costs plays important role in determining the overall cost of production.
Browse our other Reports:
- Aircraft Tires Industry Procurement Intelligence: The global aircraft tires market was valued at USD 1.6 billion in 2020 and it is expected to grow at a CAGR of 4-5% from 2020 to 2027.
- Employee Assistance Program Market Procurement Intelligence: The North American market for employee assistance programs was valued at USD 3.5 billion in 2020 and is expected to grow at a modest CAGR of 1.8% till 2025.
- Conveyor Belts Market Procurement Intelligence: The global market for conveyor belts was valued at USD 4.5 billion in 2020 and is expected to grow at a steady CAGR of 3.36% to reach USD 5.3 billion by 2025.
Key Players:
- GlaxoSmithKline plc
- Pfizer
- Sanofi Pasteur
- Merck & Co.
- CSL Limited
- Emergent BioSolutions, Inc.
- Johnson & Johnson
- AstraZeneca
- Serum Institute of India Pvt. Ltd.
- Bavarian Nordic
- Mitsubishi Tanabe Pharma Corporation
- Daiichi Sankyo Company
- PanaceaBiotec
- Bharat Biotech
- Sinovac Biotech Ltd
The global vaccine industry features a moderately consolidated landscape with the leading players contributing around 55% of the market share. Industry leaders are strengthening their presence through multiple mergers and acquisitions.
Check out the featured Add-on Services offered with Vaccine Market Procurement Intelligence Report.
